FormWeb • Article

UNC Health

UNC Health Medication Formulary

Change Request Form Chemical/SDS Search UNC Health.org

Webpage Links

Add Formweb to your mobile device

Android iOS

Click here to submit safety event reports via SAFE

UNC Health

UNC Health Medication Formulary

Change Request Form Chemical/SDS Search UNC Health.org

<< Back to News

System Formulary Update
Antineoplastic Agents

Situation

The evaluation to update restrictions on Antineoplastic agents for outpatient use only was approved in July 2022.

Background

A review was conducted on the current System and Medical Center restriction criteria on antineoplastic agents and identified a list of potential medications that could be restricted for “outpatient use only” at the System and Medical Center level.

Assessment/Recommendations

System P&T voted to restrict the following products to outpatient, clinic use only (i.e. no inpatient use) at UNC Medical Center and a System-level:

Aldo-Trastuzumab emtansine (Kadcyla)
Atezolizumab (Tecentriq)
BCG Live (Tice BCG)
Brentuximab vedotin (Adcetris)
Carfilzomib (kyprolis)
Cemiplimab (Libtayo)
Daratumumab IV (Darzalex)
Daratumumab-hyaluronidase SubQ (Darzalex Faspro)
Durvalumab (Imfinzi)
Elotuzumab (Empliciti)
Enfortumab vedotin (Padcev)
Eribulin mesylate (Halaven)
Fam-Trastuzumab deruxtecan (Enhertu)
Ipilimumab (Yervoy)

Isatuximab (Sarclisa)
Mitomycin IV (Mutamycin)
Necitumumab (Portrazza)
Nivolumab (Opdivo)
Paclitaxel protein-bound (Abraxane)
Panitumumab (Vectibix)
Pembrolizumab (Keytruda)
Pentostatin (Nipen)
Polatuzumab vedotin (Polivy)
Pralatrexate (Folotyn)
Romidepsin (Istodax)
Siltuximab (Sylvvant)
Talimogene Iaherparepvec (Imlygic)
Trabectidine (Yondelis)

Formulary/Epic changes will Go-Live on Tuesday, August 30, 2022.

This site is intended for the staff of UNC Health.
While others may view accessible pages, UNC Health makes no warranty, express or implied,
as to the use of this information outside of UNC Health.